Sterile sometribove zinc suspension. See No. 059945 in Sec. Use may result in reduced pregnancy rates and, in first calf heifers, an increase in days open. Use of the product has also been associated with increases in cystic ovaries and disorders of the uterus during the treatment period. Also, the incidence of retained placenta may be higher following subsequent calving.
Treated cows are at an increased risk for clinical mastitis and subclinical mastitis.
In some herds, use has been associated with increases in somatic cell counts in milk. Care should be taken to differentiate increased body temperature due to use of this product from an increased body temperature that may occur due to illness. Use may result in an increase in digestive disorders such as indigestion, bloat, and diarrhea. Use has been associated with reductions in hemoglobin and hematocrit values during treatment. 500 milligrams of sometribove zinc every 14 days beginning during the ninth week after calving and continuing until the end of lactation.